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Abstract
Pharmacological reduction of glucose availability with 2-deoxyglucose (2DG) suppresses pulsatile
luteinizing hormone (LH) secretion in rats and growth-retarded lambs. Gonadal steroids enhance the
glucoprivic suppression of LH secretion in rats. The present study determined if corticotropin-
releasing hormone (CRH) plays a role in mediating oestrogen-dependent and -independent
glucoprivic suppression of LH secretion. The study was conducted in ovariectomized (OVX) rats
some of which received Silastic implants containing oestradiol-17b (OE
2
) dissolved in peanut oil at
20 mg/ml to produce a physiological plasma level of OE
2
(30 pg/ml). Seven days after ovariectomy,
the rats were stereotaxically implanted with a guide cannula into the third cerebral ventricle. Seven
days later, blood samples were collected through an indwelling atrial cannula every 6 min for 3 h for
LH pulse determination. After the first hour of blood sampling, a CRH antagonist, [d-Phe12,
Nle21,38]hCRF-(21–41), or vehicle was injected into the third cerebral ventricle through the implanted
cannula before 2DG administration through the indwelling atrial cannula. Pulsatile LH secretion was
suppressed by 2DG (200 mg/kg b.w.) in the vehicle-treated rats bearing OE
2
implants. The CRH
antagonist (5.65 nmol) blocked the suppressive effect of 2DG on pulsatile LH secretion in the OE
2
-
treated OVX animals. On the other hand, in the absence of oestrogen, the effect of a twice greater
dose of 2DG (400 mg/kg b.w.) was not blocked by five times greater amount of CRH antagonist
(28.3 nmol). These results suggest the mechanisms mediating glucoprivic suppression of LH
secretion involve two components: one is oestrogen-dependent and the other oestrogen-
independent. CRH may be involved in the oestrogen-dependent component of glucoprivic
suppression of LH secretion but not the oestrogen-independent one.
The reduction of glucose availability is considered as one of that noradrenergic input to the PVN suppresses LH secretion
through a CRH-dependent pathway in the presence of oestro-the factors suppressing LH secretion under nutritional stress.
Pharmacological reduction of glucose availability with gen or through a CRH-independent pathway in the absence
of this steroid. This is because local noradrenaline injection2-deoxyglucose (2DG) interrupts oestrous cyclicity in Syrian
hamsters (1), and suppresses pulsatile luteinizing hormone into the PVN suppresses LH secretion through stimulating
CRH release in oestradiol-17b (OE2)-primed ovariectomized(LH) secretion in lambs (2) and rats (3–5). Our previousstudy in female rats suggested that fasting activates the (OVX ) rats, but it causes a transient suppression that is not
mediated by CRH in OVX animals (7). Accordingly, wecatecholaminergic input from the solitary tract nucleus to the
paraventricular nucleus (PVN ) to stimulate corticotropin- propose that fasting stress suppresses LH secretion in a CRH-
dependent/oestrogen-dependent manner and a CRH-releasing hormone (CRH) release and then suppress gonad-
otropin-releasing hormone/LH secretion (6). It is thought independent/oestrogen-independent manner.
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Glucose availability is sensed by a glucose sensitive area in with CRH antagonist (5.65 nmol ) or vehicle into the third
cerebral ventricle before 2DG administration at the dose ofthe lower brain stem, such as the area postrema and the
information is sent to the PVN via the noradrenergic pathway. 200 mg/kg b.w. In the vehicle-treated animals, 2DG transi-
ently suppressed pulsatile LH secretion. In contrast, pulsatileThe existence of this pathway, which may be similar to that
mediating fasting-induced suppression of LH secretion, is LH secretion was not blocked by 2DG treatment when the
animals received an intracerebroventricular (i.c.v.) injectionbased on the following evidence: central administration of
2DG suppresses pulsatile LH secretion in rats (3) and lambs of the CRH antagonist. There was significant (P<0.05)
difference in the percent change in mean plasma LH concen-(2); lesions of the area postrema, a circumventricular organ
in the caudal brain stem, prevent the effect of 2DG on normal tration before and after 2DG treatment between the vehicle-
and CRH antagonist-injected groups (Mann-Whitney U-oestrous cyclicity in Syrian hamsters (8); glucoprivation
stimulates noradrenaline release in the PVN; and the blockade test, Fig. 1).
Figure 2 shows representative profiles of plasma LH levelsof catecholamine synthesis in the PVN nullifies the glucoprivic
suppression of LH secretion (5). In addition, 2DG suppresses in the OVX individuals treated with 2DG (400 mg/kg b.w.)
after i.c.v. injection of a CRH antagonist (28.3 nmol ) orLH secretion in the presence or absence of sex steroids in
both genders, with steroid-treated animals being more sensit- vehicle. Pulsatile LH secretion was suppressed by 2DG in
both vehicle-injected and CRH antagonist-injected groups.ive to the glucoprivation (4). In this regard, glucoprivic
suppression of LH secretion may be mediated by a CRH- Pretreatment of animals with the CRH antagonist at
28.3 nmol did not affect the 2DG-induced suppression of LHdependent and/or CRH-independent mechanism.
The present study was designed to determine whether CRH pulses. There was no significant difference in the percent
change in mean plasma LH concentration between the groupsmediates the oestrogen-dependent or oestrogen-independent
2DG effect on pulsatile LH secretion in female rats. (Mann-Whitney U-test, Fig. 2).
DiscussionResults
Figure 1 shows the representative profiles of plasma LH Our previous study revealed that oestrogen enhances the
2DG effect to inhibit pulsatile LH secretion, because 2DGlevels in OE2-treated OVX individuals, which were injected
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F. 1. () Representative profiles of plasma LH concentrations in OE2-primed OVX rats. CRH antagonist (5.65 nmol ) or vehicle was injected intothe third cerebral ventricle before the intravenous injection of 2DG (200 mg/kg b.w.) at arrows. Blood samples were collected every 6 min for 3 h.
Arrowheads indicate peaks of LH pulses determined by PULSAR computer program. () Per cent change in mean plasma LH concentrations before
and after 2DG treatment in OE2-primed OVX rats. Values are the mean±SEM. Numbers in columns indicate the number of animals used in eachgroup. *P<0.05 (vs vehicle-injected group).
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F. 2. () Representative profiles of plasma LH concentrations in OVX rats, which were injected with CRH antagonist (28.3 nmol ) or vehicle before
2DG (400 mg/kg b.w.) treatment at arrows. Arrowheads indicate peaks of LH pulses. () Per cent change in mean plasma LH concentrations before
and after 2DG treatment in OVX rats. Numbers in columns indicate the number of animals used in each group. See Fig. 1 for details.
suppresses LH secretion at 200 mg/kg b.w. in steroid-treated of evidence indicate that oestrogen is involved in activating
CRH production or release in the PVN, since the primaryrats, but not in females without steroid treatment (4). In the
present study, therefore, the minimum doses of 2DG were transcript for CRH was increased by endotoxin lipopoly-
saccharide and c-fos mRNA was increased in CRH-immuno-chosen to induce suppression of LH secretion in both OVX
and OE2-treated OVX animals according to the above- reactive cells on the morning of pro-oestrus in female rats
(10). Both corticotropin release and corticosterone release inmentioned result. The CRH antagonist at the larger dose
(28.3 nmol ) was ineffective in preventing the glucoprivic response to restraint stress were greater in pro-oestrus com-
pared with other phases of oestrous cycle and these responsessuppression of LH release in OVX animals. This dose of the
antagonist in OVX rats was five times as much as that was were also higher in OE2-treated OVX rats than OVX rats(11). Taken together, the increased sensitivity to 2DG in theused in OE2-primed OVX rats in the present study. It isreported that [-Phe12, Nle21,38]hCRF-(21–41) used in the presence of oestrogen might be due to the activation of CRH
production or release by oestrogen. On the other hand, thepresent study is approximately 15 times more potent than
that of a-helical CRF-(9–41) in terms of antagonizing cortico- 2DG may not stimulate CRH to the level sufficient to
suppress LH secretion in the absence of oestrogen and,tropin release (9). a-Helical CRF-(9–41) at 26 nmol i.c.v.
injection into the third cerebral ventricle was effective in therefore, the higher amount of 2DG could suppress LH
secretion through a pathway other than CRH release.preventing the suppression of LH release in rats that had
fasted for 48 h (6). Therefore, the doses of 2DG and CRH- Another possibility is that opioidergic system mediating CRH
action may be modulated by oestrogen, since the suppressiveantagonist chosen in the present study are based on the
previous experiments and seem to be within reasonable ranges effect of CRH on LH secretion is mediated through opioid-
ergic system (12, 13) and naloxone-induced LH secretion isto evaluate their effect.
In the present study, 2DG suppressed LH secretion in both dependent upon the presence of gonadal steroids in rats
(14, 15).OVX and OE2-treated OVX rats, but this effect was blockedby the CRH antagonist at a lower dose in OE2-treated OVX Arginine vasopressin (AVP) has been reported to mediatesuppressive effects of stress on LH secretion (16), and to playanimals. This raises the possibility that reduced glucose
availability suppresses LH secretion through stimulating a role in compensation for the CRH deficiency (17). In
addition, AVP and CRH synergistically stimulate cortico-CRH release in the presence of oestrogen, but through
another pathway in the absence of oestrogen. Several lines tropin release from the isolated perfused anterior pituitary
© 1999 Blackwell Science Ltd, Journal of Neuroendocrinology, 11, 101–105
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Statistical analysiscells (18). In this context, AVP may have a co-operative
LH pulses were identified by the PULSAR computer program (21). Thefunction with CRH or even an alternative function to CRH
criteria for LH pulse detection have been previously described (22). Per centin oestrogen-independent glucoprivic suppression of LH.
changes in mean plasma LH concentration before and after 2DG treatmentThese results suggest the mechanisms mediating glucoprivic were determined by calculating the ratio of the difference in mean plasma
suppression of LH secretion involve two components: one is LH concentrations between the pre- and post-2DG treatment periods to the
mean LH concentration before 2DG treatment in individual animals.oestrogen-dependent and the other oestrogen-independent.
Statistical differences of the percent change in mean plasma LH concentrationCRH may be involved in the oestrogen-dependent component
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One week after the ovariectomy, a stainless steel guide cannula (22 gauge;
Plastic Products Co., Roanoke, VA, USA) was stereotaxically implanted into
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